Abbott enters global partnership to connect its world-leading continuous glucose monitoring system with medtronic's insulin delivery devices

Unique partnership with medtronic will enable continuous glucose monitoring (cgm) sensors based on abbott's freestyle libre sensing technology to integrate with medtronic's insulin delivery systems abbott now has partnerships with four of the largest companies that develop automated insulin delivery systems – offering more choices to people around the world to benefit from connectivity with libre technology abbott park, ill., aug. 7, 2024 /prnewswire/ -- abbott (nyse: abt) today announced a unique global partnership with medtronic to collaborate on an integrated continuous glucose monitoring (cgm) system based on abbott's most advanced, world-leading1 freestyle libre technology that will connect with medtronic's automated insulin delivery (aid) and smart insulin pen systems.
ABT Ratings Summary
ABT Quant Ranking